Mutation Analysis of CYP2D6 Locus in the Korean Population: Identification of Rare Poor Metabolizer Alleles at the Nucleotide Level

Molecules and Cells

Volumn 8, Issue 6, 1998, Pages 758-763

  Ryu, Seung Wook ^a   Kim, Yung Jin ^b   Kim, Eunhee ^a  

^a PaiChai University   (South Korea)

^b Chungnam National University   (South Korea)

Author keywords

CYP2D6; Korean; PM

Indexed keywords

CYTOCHROME P450 2D6; DNA; PRIMER DNA;

ALLELE; ARTICLE; GENETICS; HUMAN; KOREA; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

ALLELES; CYTOCHROME P-450 CYP2D6; DNA; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; HUMANS; KOREA; MUTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH;

EID: 0032585361     PISSN: 10168478     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Alvan, G. (1991) Clinical consequences of polymorphic drug oxidation. Fundam. Clin. Pharm. 5, 209-228.
2. Alvan, G., Bechtel, P., Iselius, L., and Reimy, U. G. (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur. J. Clin. Pharmacol. 39, 533-537.
3. Bertilsson, L., Lou, Y. Q., Du, Y. L., Liu, Y., Kuang, T. Y., Lia, X. M., Wang, K. Y., Reviriego, J., Iselius, L., and Sjoqvist, F. (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin. Pharmacol. Ther. 51, 388-397.
4. Dahl, M. L., Yue, Q. Y., Roh, H. K., Johansson, I., Sawe, J., Sjoqvist, F., and Bertilsson, L. (1995) Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean. Japanese and Chinese subjects. Pharmacogenetics 5, 159-164.
5. Daly, A. K., Brockmoller, J., Broly, F., Eichelbaum, M., Evans, W. E., Gonzalez, F. J., Huang, J. D., Idle, J. R., Ingelman-Sundberg, M., Ishizaki, T., Jacqz-Aigrain, E., Meyer, U. A., Nebert, D. W., Steen, V. M., Wolf, C. R., and Zanger, U. M. (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6, 193-201.
6. Dolzan, V., Rudolf, Z., and Breskvar, K. (1995) Human CYP2D6 gene polymorphism in Slovene cancer patients and healthy controls. Carcinogenesis 16, 2675-2678.
7. Gonzales, F. J., Skoda, R. C., and Kimura, S. (1988) Characterization of the common genetic defect in humans deficient in dcbrisoquine metabolism. Nature 331, 442-446.
8. Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., and Wolf, C. R. (1990) Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347, 773-776.
9. Guttendorf, R. J. and Wedlund, P. J. (1992) Genetic aspects of drug disposition and therapeutics. J. Clin. Pharmacol. 32, 107-117.
10. Hanioka, N., Kimura, S., Meyer, U. A., and Gonzalez, F. J. (1990) The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934fA base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am. J. Hum. Genet. 47, 994-1001.
11. Hou, Z. Y., Pickle, L. W., Meyer, P.S., and Woosley, R. L. (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin. Pharmacol. Ther. 49, 410-419.
12. Inaba, T., Jurima, M., Mahon, W. A., and Kalow, W. (1985) In vitro inhibition studies of two isozymes of human liver cytochrome P-450: Mephenytoin hydroxylase and Sparteine Monooxygenase. Drug Metabolism and Disposition 4, 443-448.
13. Johansson, I., Oscarson, M., Yue, Q. Y., Bertilsson, L., Sjoqvist, F., and Magnus, I. S. (1994) Genetic analysis of Chinese cytochrome P4502D locus: chatacterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol. Pharmacol. 46, 452-459.
14. Jurima, M., Inaba, T., and Kalow, W. (1983) sparteine oxidation by the human liver: Absence of inhibition, Clin. Pharmacol. Ther. 35, 426-428.
15. Kimura, S., Umeno, M., Skoda, R. C., Meyer, U. A., and Gonzalez, F. J. (1989) The human debrisoquin 4-hydroxylase (CYP2D) locus: sequence and isolation of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am. J. Hum. Genet. 45, 889-904.
16. Mahgoub, A., Idle, J. R., Dring, L. G., Lancaster, R., and Smith, R. L. (1997) Polymorphic hydroxylation of debrisoquine in man. Lancet 2, 584-586.
17. Nakamura, K., Goto, F. Ray, W. A., McAllister, C. B., Jacqz, E., Wilkinson, G. R., and Branch, R. A. (1985) Interethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin. Pharmacol. Ther. 38, 402-408.
18. Nebert, D. W., Nckinnon, R. A., and Puga, A. (1996) Human Drug-Metabolizing enzyme polymorphisms: Effects on Risk of toxicity and cancer. DNA Cell Biol. 15, 273-280.
19. Roh, H. K., Dahl, M. L., Johansson, I., Maguns, I. S., Cha, Y. N., and Bertilsson, L. (1996) Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 6, 441-447.
20. Sachse, C., Brockmoller, J., Bauer, S., and Roots, I. (1997) Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences. Am. J. Hum. Genes. 60, 284-295.
21. Schellens, J. H. M., Vanderwart, J. H. F., and Breimer, D. D. (1990) Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects. Br. J. Clin. Pharmacol. 29, 665-671.
22. Skoda, R. C., Gonzalez, F. J, Demierre, A., and Meyer, U. A. (1988) Two mutant alleles of the human cytochrome P450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. Proc. Natl. Acad. Sci. USA 85, 5240-5243.
23. Sohn, D. R, Shin, S. G., Park, C. W., Kusaka, M., and Ishizaki, T. (1991) Metoprolol oxidation polymorphism in a Korean population: comparison with native Japanese and Chinese populations. Br. J. Clin. Pharmacol. 32, 504-507.
24. Stiicker, I., Cosme, J., Laurent, P., Cenee, S., Beaune, P., Bignon, J., Depierre, A., Milleron, B., and Hemon, D. (1995) CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 16, 2759-2764.
25. Veronese, M. E. and McLean, S. (1991) Metabolism of paracetamol and phenacetin in relation to debrisoquine oxidation phenotype. Eur. J. Clin. Pharmacol. 40, 547-552.